| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1;;LPA receptor 1 |
| WB Predicted band size | Calculated MW: 41 kDa ; Observed MW: 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human LPA receptor 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
1. **"Development of a monoclonal antibody specific for LPA1 (EDG2) receptor and its application in immunohistochemical analysis of human tissues"**
- 作者：Ohta H. 等
- 摘要：该研究开发了一种针对LPA1(EDG2)受体的高特异性单克隆抗体，验证了其在Western blot和免疫组化中的应用，并揭示了LPA1在多种癌症组织中的高表达。
2. **"Targeting lysophosphatidic acid receptor 1 (EDG2) in pulmonary fibrosis using a novel neutralizing antibody"**
- 作者：Tager A.M. 等
- 摘要：研究设计了一种中和EDG2受体的抗体，通过动物模型证明其能抑制LPA信号通路，显著减轻肺纤维化病变，提示其治疗潜力。
3. **"Characterization of EDG2 receptor signaling in glioblastoma via antibody-mediated receptor blockade"**
- 作者：Bian D. 等
- 摘要：利用抗EDG2抗体阻断胶质母细胞瘤细胞的受体活性，发现其抑制肿瘤迁移和侵袭，揭示了LPA1在癌症进展中的关键作用。
4. **"EDG2 antibody-based detection of lysophosphatidic acid receptor expression in inflammatory diseases"**
- 作者：Chun J. 等
- 摘要：通过抗EDG2抗体分析类风湿性关节炎等炎症组织中LPA1的表达，表明受体上调与炎症反应相关，为靶向治疗提供依据。
(注：以上文献信息为模拟示例，实际引用需根据具体研究核实。)
The EDG2 antibody targets the Endothelial Differentiation Gene 2 (EDG2), also known as lysophosphatidic acid receptor 1 (LPA₁), a G protein-coupled receptor (GPCR) that binds lysophosphatidic acid (LPA). LPA is a bioactive phospholipid involved in diverse physiological processes, including cell proliferation, migration, and survival, as well as pathological conditions like fibrosis, cancer, and inflammation. EDG2/LPA₁ is widely expressed in tissues such as the brain, cardiovascular system, and immune cells, playing critical roles in embryonic development, neural signaling, and tissue repair.
EDG2 antibodies are essential tools for studying LPA₁ expression, localization, and function in vitro and in vivo. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate receptor dynamics in disease models. Researchers also employ EDG2-blocking antibodies to dissect LPA-mediated signaling pathways (e.g., via Rho, MAPK, or PLC) and evaluate therapeutic potential in disorders driven by aberrant LPA signaling. For instance, EDG2 antibodies have been applied in cancer research to explore LPA₁'s role in tumor metastasis or in fibrosis studies to assess its contribution to extracellular matrix remodeling.
The development of EDG2-targeted therapies, including small-molecule inhibitors, underscores the receptor's clinical relevance. However, antibodies remain vital for mechanistic studies and biomarker validation, bridging basic research and translational applications.
×
